Tema Oncology ETF (CANC)
| Assets | $48.69M |
| Expense Ratio | 0.75% |
| PE Ratio | 26.86 |
| Shares Out | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +13.49% |
| Volume | 1,230 |
| Open | 27.95 |
| Previous Close | 27.79 |
| Day's Range | 27.54 - 27.95 |
| 52-Week Low | 24.35 |
| 52-Week High | 30.11 |
| Beta | n/a |
| Holdings | 51 |
| Inception Date | Aug 15, 2023 |
About CANC
Fund Home PageThe Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
Top 10 Holdings
43.03% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 5.44% |
| AstraZeneca PLC | AZN | 5.17% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.05% |
| Revolution Medicines, Inc. | RVMD | 4.70% |
| argenx SE | ARGX | 4.28% |
| Illumina, Inc. | ILMN | 4.18% |
| Blueprint Medicines Corporation | BPMC | 4.00% |
| Incyte Corporation | INCY | 3.94% |
| Chugai Pharmaceutical Co., Ltd. | 4519 | 3.22% |
| Exelixis, Inc. | EXEL | 3.05% |
News
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakth...
Tema Launches Two Innovative, Active ETF Thematic Strategies: Oncology & Global Royalties
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”) launches two innovative and actively managed thematic ETF offerings: the Oncology ETF (CANC) and the Global Royalties ETF (ROYA). These strategies are the...